Hemostatic risk factors for atherothrombotic disease: An epidemiologic view

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 366-373

  Folsom, A R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Atherosclerosis; Coagulation factors; Coronary disease; Fibrinogen; Fibrinolysis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; EPIDEMIOLOGICAL DATA; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0034911310     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616234     Document Type: Conference Paper

References (78)

1. Prospective study of markers of hemostatic function with risk of ischemic stroke
2. Prospective study of hemostatic factors and incidence of coronary heart disease: The Artherosclerosis Risk in Communities (ARIC) Study
3. Genetic prediction of myocardial infarction
4. Genetic determinants of arterial thrombosis
5. Vascular and haemostatic gene polymorphisms associated with non-fatal myocardial infarction: A critical review
6. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study
7. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
8. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men
9. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD)
10. Meta-analysis of the association of platelet glycoprotein IIIa P1A1/A2 polymorphism with myocardial infarction
11. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
12. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors
13. The relationship of fibrinogen and factor VII and VIII to incident cardiovascular disease and death in the elderly: Results from the cardiovascular health study
14. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study
15. Plasma fibrinogen and coronary heart disease in urban Japanese
16. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease
17. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study
18. Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update
19. Fibrinogen as a risk factor for stroke and myocardial infarction
20. Fibrinogen and risk of cardiovascular disease: Th Framingham Study
21. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
22. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
23. Haematocrit, viscosity, erythrocyte sedimentation rate: Meta-analyses of prospective studies of coronary heart disease
24. C-reactive protein, inflammation, and coronary risk
25. 2 as an independent predictor of coronary heart disease
26. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM Study in Healthy Men
27. Coagulation factor VII and the risk of coronary heart disease in healthy men
28. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: An international study
29. The structure and function of von Willebrand factor
30. Von Willebrand factor and the endothelium in vascular disease
31. Factor VIII, ABO blood group and the incidence of ischaemic heart disease
32. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study
33. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
34. Fibrinolytic activity and clotting factors in ischaemic heart disease in women
35. A prospective study of fibrinolytic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
36. Soluble thrombomodulin as a predictor of incident coronary heart disease: The ARIC Study
37. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
38. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
39. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
40. The plasminogen (fibrinolytic) system
41. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
42. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
43. Prospective study of endogenous tissue plasminogen activator and risk of stroke
44. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly
45. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study
46. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
47. A prospective study of plasminogen activator inhibitor and the risk of future myocardial infarction
48. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study
49. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
50. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
51. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
52. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction
53. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction
54. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
55. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
56. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study
57. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina
58. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
59. Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions
60. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm
61. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
62. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
63. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma
64. TAFI
65. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study
66. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects
67. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men
68. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI)
69. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
70. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
71. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
72. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women
73. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
74. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes
75. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease
76. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study
77. Thrombosis prevention trial: Randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
78. Lowering fibrinogen levels: Clinical update. BIP Study Group. Bezafibrate infarction prevention